{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:26:24Z","timestamp":1793298384759,"version":"4.5.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"48","funder":[{"DOI":"10.13039\/100004440","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["072960 and 084726"],"award-info":[{"award-number":["072960 and 084726"]}],"id":[{"id":"10.13039\/100004440","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011102","name":"Seventh Framework Programme","doi-asserted-by":"publisher","award":["FP7\/2007-2013"],"award-info":[{"award-number":["FP7\/2007-2013"]}],"id":[{"id":"10.13039\/100011102","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"publisher","award":["521-2011-2440 and 521-2014-3370"],"award-info":[{"award-number":["521-2011-2440 and 521-2014-3370"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MC_qA137929"],"award-info":[{"award-number":["MC_qA137929"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,21]]},"DOI":"10.1093\/eurheartj\/ehx467","type":"journal-article","created":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T15:14:06Z","timestamp":1500909246000},"page":"3569-3575","source":"Crossref","is-referenced-by-count":54,"title":["A common missense variant of LILRB5 is associated with statin intolerance and myalgia"],"prefix":"10.1093","volume":"38","author":[{"given":"Moneeza","family":"K Siddiqui","sequence":"first","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrielle","family":"Maroteau","sequence":"additional","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abirami","family":"Veluchamy","sequence":"additional","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksi","family":"Tornio","sequence":"additional","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Tavendale","sequence":"additional","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Carr","sequence":"additional","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ngu-Uma","family":"Abelega","sequence":"additional","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Carr","sequence":"additional","affiliation":[{"name":"Institute of Translation Medicine, University of Liverpool, Liverpool L69 3BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katyrzyna","family":"Bloch","sequence":"additional","affiliation":[{"name":"Institute of Translation Medicine, University of Liverpool, Liverpool L69 3BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Par","family":"Hallberg","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Pharmacology and Science of Life Laboratory, Uppsala University, 751 85 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qun-Ying","family":"Yue","sequence":"additional","affiliation":[{"name":"Medical Products Agency, Dag Hammarskj\u00f6lds v\u00e4g 42, 75237 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewan R","family":"Pearson","sequence":"additional","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M","family":"Colhoun","sequence":"additional","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"},{"name":"Institute of Genetics & Molecular Medicine, University of Edinburgh, Edinburgh EH4 2XU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew D","family":"Morris","sequence":"additional","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"},{"name":"Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh EH4 2XU, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleanor","family":"Dow","sequence":"additional","affiliation":[{"name":"Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"George","sequence":"additional","affiliation":[{"name":"Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Munir","family":"Pirmohamed","sequence":"additional","affiliation":[{"name":"Institute of Translation Medicine, University of Liverpool, Liverpool L69 3BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M","family":"Ridker","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Department of Medicine, Preventive Medicine, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex S F","family":"Doney","sequence":"additional","affiliation":[{"name":"Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Alfirevic","sequence":"additional","affiliation":[{"name":"Institute of Translation Medicine, University of Liverpool, Liverpool L69 3BX, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mia","family":"Wadelius","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Clinical Pharmacology and Science of Life Laboratory, Uppsala University, 751 85 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke-Hilse","family":"Maitland-van der Zee","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht Institute of Pharmaceutical Sciences, Utrecht University, 3508 TB Utrecht, The Netherlands"},{"name":"Department of Respiratory Medicine, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I","family":"Chasman","sequence":"additional","affiliation":[{"name":"Brigham and Women's Hospital, Department of Medicine, Preventive Medicine, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin N A","family":"Palmer","sequence":"additional","affiliation":[{"name":"Pat McPherson Centre for Pharmacogenetics & Pharmacogenomics, Division of Molecular & Clinical Medicine, University of Dundee, Ninewells Hospital and Medical School, Dundee DD19SY, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"PREDICTION-ADR Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,8,29]]},"reference":[{"key":"key\n\t\t\t\t20180222014158_ehx467-B1","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/eurheartj\/ehm316","article-title":". European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)","volume":"28","author":"Graham","year":"2007","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B3","volume-title":"International Comparison of Medicines Usage: Quantitative Analysis","author":"\u00d3Neill","year":"2014"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B4","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejim.2012.01.004","article-title":"Statin induced myotoxicity","volume":"23","author":"Sathasivam","year":"2012","journal-title":"Eur J Intern Med"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B5","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B6","doi-asserted-by":"crossref","first-page":"950.","DOI":"10.1136\/bmj.332.7547.950","article-title":"Atorvastatin may cause nightmares","volume":"332","author":"Gregoor","year":"2006","journal-title":"BMJ"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/0021-9150(95)05523-Y","article-title":"Long-term efficacy and tolerability of simvastatin in a large cohort of elderly hypercholesterolemic patients","volume":"116","author":"Lansberg","year":"1995","journal-title":"Atherosclerosis"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B8","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1136\/heart.88.3.234","article-title":"Long term efficacy and safety of atorvastatin in the treatment of severe type III and combined dyslipidaemia","volume":"88","author":"Dam","year":"2002","journal-title":"Heart"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1038\/clpt.2014.121","article-title":"Phenotype standardization for statin-induced myotoxicity","volume":"96","author":"Alfirevic","year":"2014","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B10","doi-asserted-by":"crossref","first-page":"291.","DOI":"10.1007\/s11883-012-0291-7","article-title":"How do we improve patient compliance and adherence to long-term statin therapy?","volume":"15","author":"Maningat","year":"2013","journal-title":"Curr Atheroscler Rep"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B11","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jval.2015.06.002","article-title":"Impact of statin adherence on cardiovascular morbidity and all-cause mortality in the primary prevention of cardiovascular disease: a population-based cohort study in Finland","volume":"18","author":"Rannanheimo","year":"2015","journal-title":"Value Health"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B12","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1161\/CIRCGENETICS.113.000395","article-title":"CKM and LILRB5 are associated with serum levels of creatine kinase","volume":"7","author":"Dube","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B13","doi-asserted-by":"crossref","first-page":"10572.","DOI":"10.1038\/ncomms10572","article-title":"Common and rare variants associating with serum levels of creatine kinase and lactate dehydrogenase","volume":"7","author":"Kristjansson","year":"2016","journal-title":"Nat Commun"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B14","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/clpt.2010.255","article-title":"Common nonsynonymous substitutions in SLCO1B1 predispose to statin intolerance in routinely treated individuals with type 2 diabetes: a go-DARTS study","volume":"89","author":"Donnelly","year":"2011","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B15","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/bcp.12269","article-title":"Electronic health records for biological sample collection: feasibility study of statin-induced myopathy using the clinical practice research datalink","volume":"77","author":"O\u2019Meara","year":"2014","journal-title":"Br J Clin Pharmacol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B16","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/CIRCGENETICS.111.961144","article-title":"Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial","volume":"5","author":"Chasman","year":"2012","journal-title":"Circ Cardiovasc Genet"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B17","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B18","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1093\/eurheartj\/ehr158","article-title":"ESC\/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)","volume":"32","author":"European Association for Cardiovascular Prevention & Rehabilitation","year":"2011","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B19","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1016\/j.jacc.2014.03.019","article-title":"Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab","volume":"63","author":"Stroes","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1002\/clc.22248","article-title":"Design and rationale of the GAUSS-2 study trial: a double-blind, ezetimibe-controlled phase 3 study of the efficacy and tolerability of evolocumab (AMG 145) in subjects with hypercholesterolemia who are intolerant of statin therapy","volume":"37","author":"Cho","year":"2014","journal-title":"Clin Cardiol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5114\/aoms.2015.49807","article-title":"Statin intolerance\u2014an attempt at a unified definition. Position paper from an International Lipid Expert Panel","volume":"11","author":"Banach","year":"2015","journal-title":"Arch Med Sci"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B22","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2014.03.003","article-title":"NLA task force on statin safety\u20132014 update","volume":"8","author":"Jacobson","year":"2014","journal-title":"J Clin Lipidol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B23","doi-asserted-by":"crossref","first-page":"e013351.","DOI":"10.1136\/bmjopen-2016-013351","article-title":"Cohort profile: the Scottish Research register SHARE. A register of people interested in research participation linked to NHS data sets","volume":"7","author":"McKinstry","year":"2017","journal-title":"BMJ Open"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B24","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.jacc.2010.09.082","article-title":"Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50\u2009mg\/dl with rosuvastatin: the JUPITER trial (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin)","volume":"57","author":"Hsia","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B25","volume-title":"R: A Language and Environment for Statistical Computing","author":"R Development Core Team","year":"2008"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J Stat Softw"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B27","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.immuni.2016.01.009","article-title":"Poor repair of skeletal muscle in aging mice reflects a defect in local, interleukin-33-dependent accumulation of regulatory T cells","volume":"44","author":"Kuswanto","year":"2016","journal-title":"Immunity"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B28","doi-asserted-by":"crossref","first-page":"762506.","DOI":"10.1155\/2015\/762506","article-title":"Statins increase the frequency of circulating CD4+ FOXP3+ regulatory T cells in healthy individuals","volume":"2015","author":"Rodriguez-Perea","year":"2015","journal-title":"J Immunol Res"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B29","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/ni904","article-title":"Foxp3 programs the development and function of CD4+CD25+ regulatory T cells","volume":"4","author":"Fontenot","year":"2003","journal-title":"Nat Immunol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B30","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1089\/bio.2015.29031.hmm","article-title":"The Genotype-Tissue Expression (GTEx) project","volume":"13","author":"Carithers","year":"2015","journal-title":"Biopreserv Biobank"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B31","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1126\/science.1262110","article-title":"The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans","volume":"348","author":"Human genomics","year":"2015","journal-title":"Science"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B32","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/j.jacc.2013.02.074","article-title":"Simvastatin impairs exercise training adaptations","volume":"62","author":"Mikus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B33","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","author":"Stroes","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B34","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J Pathol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B35","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B36","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1001\/archneur.62.11.1709","article-title":"Muscle coenzyme q10 level in statin-related myopathy","volume":"62","author":"Lamperti","year":"2005","journal-title":"Arch Neurol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B37","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/mus.24541","article-title":"Clinical and genetic associations of autoantibodies to 3-hydroxy-3-methyl-glutaryl-coenzyme a reductase in patients with immune-mediated myositis and necrotizing myopathy","volume":"52","author":"Limaye","year":"2015","journal-title":"Muscle Nerve"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B38","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra0801327","article-title":"Rhabdomyolysis and acute kidney injury","volume":"361","author":"Bosch","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B39","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.clpt.2006.09.003","article-title":"Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance","volume":"80","author":"Neuvonen","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1080\/17425255.2016.1227791","article-title":"Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters","volume":"13","author":"Tornio","year":"2017","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B41","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1345\/aph.1Q110","article-title":"Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population","volume":"45","author":"Amend","year":"2011","journal-title":"Ann Pharmacother"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B42","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2014"},{"key":"key\n\t\t\t\t20180222014158_ehx467-B43","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1001\/jama.2016.3608","article-title":"Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial","volume":"315","author":"Nissen","year":"2016","journal-title":"JAMA"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/48\/3569\/24120885\/ehx467.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,22]],"date-time":"2018-02-22T01:42:14Z","timestamp":1519263734000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/38\/48\/3569\/4096401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,29]]},"references-count":43,"journal-issue":{"issue":"48","published-online":{"date-parts":[[2017,8,29]]},"published-print":{"date-parts":[[2017,12,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx467","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12,21]]},"published":{"date-parts":[[2017,8,29]]}}}